<SEC-DOCUMENT>0001104659-22-058348.txt : 20220510
<SEC-HEADER>0001104659-22-058348.hdr.sgml : 20220510
<ACCEPTANCE-DATETIME>20220510172511
ACCESSION NUMBER:		0001104659-22-058348
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220510
FILED AS OF DATE:		20220510
DATE AS OF CHANGE:		20220510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evaxion Biotech A/S
		CENTRAL INDEX KEY:			0001828253
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			G7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39950
		FILM NUMBER:		22911155

	BUSINESS ADDRESS:	
		STREET 1:		BREDGADE 34E
		CITY:			COPENHAGEN K
		STATE:			G7
		ZIP:			1260
		BUSINESS PHONE:		4531262615

	MAIL ADDRESS:	
		STREET 1:		BREDGADE 34E
		CITY:			COPENHAGEN K
		STATE:			G7
		ZIP:			1260
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2215076d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>PURSUANT TO SECTION&nbsp;13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>For the&nbsp;month of May 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>Commission File Number: 001-39950</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>Evaxion Biotech A/S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>(Exact Name of Registrant as Specified
in Its Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>Dr.&nbsp;Neergaards Vej 5f</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>DK-2970 Hoersholm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>Denmark</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>(Address of principal executive offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt 0pt 0pt">Indicate by check mark whether the registrant files or will file
annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Form&nbsp;20-F <FONT STYLE="font-family: Wingdings">&#120;</FONT>
Form&nbsp;40-F <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt 0pt 0pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K
in paper as permitted by Regulation S-T Rule&nbsp;101(b)(1): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt 0pt 0pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K
in paper as permitted by Regulation S-T Rule&nbsp;101(b)(7): <FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 58.5pt 0pt 59.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 58.5pt 0pt 59.6pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 58.5pt 0pt 59.6pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 58.5pt 0pt 59.6pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Announcement of Successful Production of Personalized
Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On May 10, 2022, Evaxion Biotech
A/S (the &ldquo;Company&rdquo;) issued a press release announcing that it has successfully produced all batches of personalized cancer
immunotherapies for all patients enrolled in the Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Furnished
as Exhibit 99.1 to this Report on Form&nbsp;6-K&nbsp;is the Company&rsquo;s Press Release dated May 10, 2022, related to the successful
production of personalized cancer immunotherapies in the Company&rsquo;s Phase 1/2a clinical trial for its product candidate EVX-02.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INCORPORATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This report on Form&nbsp;6-K&nbsp;shall
be deemed to be&nbsp;incorporated by reference&nbsp;in that certain registration statement on<B>&nbsp;</B>Form&nbsp;S-8&nbsp;(File&nbsp;No.&nbsp;333-255064)&nbsp;(including
any prospectus forming a part of such registration statement) of the Company and to be a part thereof from the date on which this report
is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 58.5pt 0pt 59.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><U>Exhibit No.</U></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><U>Description</U></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: left"><A HREF="tm2215076d1_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="tm2215076d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release dated May 10, 2022.</A></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 58.5pt 0pt 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.75pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Evaxion Biotech A/S</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.75pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; padding-right: 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 10, 2022</FONT></TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Lori Hollander.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.75pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Lori Hollander</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.75pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Vice President Financial Planning and Analysis</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 59.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2215076d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><IMG SRC="tm2215076d1_ex99-1img002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Evaxion Biotech Announces Successful Production of Personalized
Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Copenhagen,
Denmark, May 10, 2022</B></FONT> (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing
in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today
that it has successfully produced all batches of personalized cancer immunotherapies for all patients enrolled in the Phase 1/2a clinical
trial of EVX-02 in adjuvant melanoma.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Birgitte
R&oslash;n&oslash;, Chief Scientific Officer of Evaxion,</B></FONT> said: &ldquo;I am extremely proud that the team behind EVX-02 has
shown that this complex production chain is feasible and that we can provide truly unique, personalized DNA vaccines within a critical
time window. And we are delighted that we mastered all steps in the production process. Every cancer is unique, as is every immune system,
and this is why we create cancer therapies that are one size fits one &ndash; and only one.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">She
continues: &ldquo;With the release of the final batch, we confirmed our manufacturing process, which we believe will allow us to progress
our DNA cancer immunotherapy programs into larger global trials to explore the clinical benefits of the compounds further</FONT>. We have
again demonstrated our capabilities to timely deliver personalized cancer treatment tailored to the unique cancer profile of every patient
in a clinical trial.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The production process of the personalized drug product consists of
multiple steps. The sequencing of the tumor DNA is followed by AI-powered identification of the most promising therapeutic targets developed
by Evaxion's proprietary PIONEER<SUP>TM </SUP>technology. This leads to designing the personalized multi-target vaccine drug product,
which is then manufactured, released to the clinical sites, and administered to the patient.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This is the second time Evaxion has conducted a clinical trial with
personalized cancer immunotherapy, having previously used a peptide-based treatment.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About EVX-02</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #333333">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #333333">Our
EVX-02 program (NCT04455503) treats adjuvant melanoma patients with our patented DNA-based immunotherapy in combination with standard
of care. The patients are fully resected before the trial, meaning that their tumors have been successfully removed (surgically). In the
study, the focus of the therapy is to prevent disease relapse.</FONT> The EVX-02 program is a multicenter study conducted in Australia.
There are currently 16 patients enrolled in the trial.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Evaxion </B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Evaxion Biotech A/S is a clinical-stage AI-immunology&trade; platform
company decoding the human immune system to discover and develop novel immunotherapies to treat cancer, bacterial diseases, and viral
infections. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product
candidates, including three patient-specific cancer immunotherapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
more information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Corey Davis, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>cdavis@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (212) 915 2577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Source: Evaxion Biotech</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-looking statement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This announcement contains forward-looking statements
that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this announcement
regarding the Company&rsquo;s future operations, plans and objectives are forward-looking statements. Although the Company believes its
expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this announcement
about future events are subject to (i) change without notice and (ii) factors beyond the Company&rsquo;s control. These statements may
include, without limitation, any statements preceded by, followed by, or including words such as &ldquo;target,&rdquo; &ldquo;believe,&rdquo;
&ldquo;expect,&rdquo; &ldquo;hope,&rdquo; &ldquo;aim,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;contemplate,&rdquo; &ldquo;continue,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo;
&ldquo;project,&rdquo; &ldquo;will,&rdquo; &ldquo;can have,&rdquo; &ldquo;likely,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;could&rdquo;,
and other words and terms of similar meaning or the negative thereof. Actual results may differ materially from those indicated by such
forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company&rsquo;s financial
condition and need for additional capital; risks associated with the Company&rsquo;s development work; cost and success of the Company&rsquo;s
product development activities and preclinical and clinical trials; risks related to commercializing any approved pharmaceutical product
developed using the Company&rsquo;s AI platform technology, including the rate and degree of market acceptance of the Company&rsquo;s
product candidates; risks related to the Company&rsquo;s dependence on third parties including for conduct of clinical testing and product
manufacture; risks associated with the Company&rsquo;s inability to enter into partnerships; risks related to government regulation; risks
associated with protection of the Company&rsquo;s intellectual property rights; risks related to employee matters and managing growth;
risks related to the Company&rsquo;s ADSs and ordinary shares, risks associated with the pandemic caused by the coronavirus known as COVID-19
and other risks and uncertainties affecting the Company&rsquo;s business operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-looking statements are subject to inherent
risks and uncertainties beyond the Company&rsquo;s control that could cause the Company&rsquo;s actual results, performance, or achievements
to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements.
For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking
statements, as well as risks relating to the Company&rsquo;s business in general, see the risks described in the &ldquo;Risk Factors&rdquo;
section included in the Company&rsquo;s prospectus filed on February 5, 2021 and the Company&rsquo;s current and future reports filed
with, or submitted to, the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this announcement
speak only as of the date hereof, and except as required by law, the Company assumes no obligation to update these forward-looking statements
publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even
if new information becomes available in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2215076d1_ex99-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2215076d1_ex99-1img002.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "$ 2P# 2(  A$! Q$!_\0
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MYK%HVKQ!Y +7Q!XMT[^UTM)(W8PFZ'AQ-$U%9(D$XMM0CB,X62:V/Z1PKM.
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MR^?\0U>L?]):_P#@H=_X7Q_^6]=]\*?^#>35_AC\4?AS\26_X*J?\%"?$*>
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M&,8JRBHI:);.*6BT6B2T[(_@C_X.]?\ DZ;]B'_LA7Q@_P#5H>!:_O \*?\
M(L>'?^P%H_\ Z;;6OX/_ /@[U_Y.F_8A_P"R%?&#_P!6AX%K^\#PI_R+'AW_
M + 6C_\ IMM:^GS?_DG.$/\ KQFG_J4>=A/]_P S_P >&_\ 3"-F9I%'[O!8
MX"AN!N)QRVUB!R,D*V.NTU_ 1HFE7G_!>G_@X%\8Z#\5KR7Q#^R/^R-X@^(H
MTKP=I6M:-<>']6^"7[//Q%TSPE::7 M]_:=AK>@?M,?&5-!UCXF7>@VCZAXB
M^$VL1>&[/5=.BT;0/$FG_P!^TSK'\[$!4VL['/"ALDCW"JW Y(SP> ?X"_\
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MDU9RJ2G.4VUZNW:R3LKH****\8[ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0@'J,]
M?UZ@^H/<&BBDTFK-77G]X%6VL;.T>>6VMH89KHPFYF2-1/<FWA6W@:YFQYMP
MT,")!$TSNR1(D:D(H MT44P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
